Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1993-09-13
1995-10-17
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514378, 514466, 514656, 548248, 549438, A61K 3142, A61K 31275, A61K 3136, A61K 3142
Patent
active
054591635
ABSTRACT:
A pharmaceutical composition for use in the treatment of chronic Graft-versus-host diseases as well as autoimmune diseases, in particular for the treatment of systemic lupus erythematosus containing as an active ingredient at least one compound of the formulae 1 or 2 ##STR1## the latter being present per se or in the form of a physiologically tolerable salt.
The invention also relates to a dosage unit form of said pharmaceutical composition and a method of treating chronic Graft-versus host diseases as well as autoimmune diseases, in particular systemic lupus erythematosus.
REFERENCES:
patent: 4061767 (1977-12-01), Ertel et al.
patent: 4284786 (1981-08-01), Kammerer et al.
patent: 4343796 (1982-08-01), Groen
patent: 4435387 (1984-03-01), Schaub et al.
patent: 4435407 (1984-03-01), Walker
patent: 4636513 (1987-01-01), Kammerer et al.
patent: 4965276 (1990-10-01), Bartlett et al.
Ackermann, N. R., et al., "The Effects of D-penicilliname in the MRL/1 Mouse, " Adv. Infl. Res., 7: 277-286 (1984).
"I. Disease Modifying Action on Adjuvant Arthritis of the Rat, " Intl. J. Immunopharmac., 7(1): 7-18 (1965).
Bartlett, R. R., "Immunopharmacological Profile of HWA 486, a Novel Isoxazol Derivative-11. In vivoImmunomodulating Effects Differ from Those of Cyclophosphamide, Prednisolone, or Cyclosporin A," Intl. J. Immunopharmac., 8(2): 199-204 (1986).
Burlingame, M., et al., "Treatment of Systemic Lupus Erythematosus, " Drug Intelligence and Clincial Pharmacy, 22 283-289 (1988).
Gleichmann, E., et al., "A Systemic Lupus Erythematosus (SLE)-like Disease in Mice Induced by Abnormal T-B Cell Cooperation. Preferential Formation of Autoantibodies Characteristic of SLE, " Eur. J. Immunol., 12: 152-159 (1982).
Pisetsky, D., "Systemic Lupus Erythematosus, " Adv. Rheum., Medical Clinics of North America. 70(2): 337-353 (1986).
Popovic, S., et al., "The Use of the Murine Chronic Graft vs. Host (CGVH) Disease, A Model for Systemic Lupus Erythematosus (SLE), for Drug Discovery." Agents and Actions. 21(3/4): 284-286 (1987).
Stecher, V. J., et al., "Disease Modifying Anti-Rheumatic Drugs, " Annual roots in Medicinal Chemistry, 18: 171-179 (1983).
Oxford Textbook of Medicine, Second Edition, eds. D. J. Weatherall, J. G. G. Ledingham and D. A. Warrell, vol. 2, pp. 16.20-16.28 and 21.211-21.216 (1987).
Bartlett Robert R.
Kammerer Friedrich-Johannes
Schleyerbach Rudolph
Criares Theodore J.
Hoechst Aktiengesellschaft
LandOfFree
Medicament to combat autoimmune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament to combat autoimmune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament to combat autoimmune diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-597668